QJM, Vol 91, Issue 6 393-399, Copyright © 1998 by Oxford University Press
KM Kalkner, L Ronnblom, AK Karlsson Parra, M Bengtsson, Y Olsson and K Oberg
Alpha interferons have become effective palliative treatments for patients
with neuroendocrine tumours such as carcinoids and endocrine pancreatic
tumours. However, several reports indicate an increased incidence of both
autoantibodies and autoimmune diseases in patients treated with
interferon-alpha (IFN-alpha). We studied the development of antibodies
against double-stranded DNA (dsDNA) and clinical signs of autoimmune
disease in 214 patients with malignant carcinoids or endocrine pancreatic
tumours consecutively admitted for treatment with IFN-alpha. Seventeen
patients (8%) developed antibodies against dsDNA, predominantly females (12
females and 5 males). One patient had clinical and laboratory signs of
polymyositis. Among the other 16 patients, three developed hypothyroidism
and in six patients the anti- dsDNA autoantibodies normalized despite
continuing therapy. Although a significant number of patients developed
autoantibodies against dsDNA, overt autoimmune disease related to these
antibodies is a rare event and many patients spontaneously normalize these
titres despite continuing IFN-alpha treatment.
ORIGINAL PAPERS
Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon
Department of Internal Medicine, University Hospital, Uppsala, Sweden.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Bolland and A. Garcia-Sastre Vicious circle: systemic autoreactivity in Ro52/TRIM21-deficient mice J. Exp. Med., August 3, 2009; 206(8): 1647 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Gogas, J. Ioannovich, U. Dafni, C. Stavropoulou-Giokas, K. Frangia, D. Tsoutsos, P. Panagiotou, A. Polyzos, O. Papadopoulos, A. Stratigos, et al. Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon N. Engl. J. Med., February 16, 2006; 354(7): 709 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ronnblom and G. V. Alm A Pivotal Role for the Natural Interferon {alpha}-producing Cells (Plasmacytoid Dendritic Cells) in the Pathogenesis of Lupus J. Exp. Med., December 17, 2001; 194(12): F59 - F64. [Full Text] [PDF]
|
|
|
|
|
|
A. Dzionek, Y. Sohma, J. Nagafune, M. Cella, M. Colonna, F. Facchetti, G. Gunther, I. Johnston, A. Lanzavecchia, T. Nagasaka, et al. BDCA-2, a Novel Plasmacytoid Dendritic Cell-specific Type II C-type Lectin, Mediates Antigen Capture and Is a Potent Inhibitor of Interferon {alpha}/{beta} Induction J. Exp. Med., December 17, 2001; 194(12): 1823 - 1834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A A Bengtsson, G Sturfelt, L Truedsson, J Blomberg, G Alm, H Vallin, and L Ronnblom Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies Lupus, November 1, 2000; 9(9): 664 - 671. [Abstract] [PDF]
|
|
|
|
 |
|
 U. Bave, G. V. Alm, and L. Ronnblom The Combination of Apoptotic U937 Cells and Lupus IgG Is a Potent IFN-{alpha} Inducer J. Immunol., September 15, 2000; 165(6): 3519 - 3526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. D. Hengstman, O. J. M. Vogels, H. J. ter Laak, T. de Witte, and B. G. M. van Engelen Myositis during long-term interferon-{alpha} treatment Neurology, June 13, 2000; 54(11): 2186 - 2186. [Full Text] [PDF]
|
|
|
|
|
|
H. Vallin, A. Perers, G. V. Alm, and L. Ronnblom Anti-Double-Stranded DNA Antibodies and Immunostimulatory Plasmid DNA in Combination Mimic the Endogenous IFN-{alpha} Inducer in Systemic Lupus Erythematosus J. Immunol., December 1, 1999; 163(11): 6306 - 6313. [Abstract] [Full Text] [PDF]
|
|